Johnson & Johnson
(JNJ-$95.63) isn’t waiting until decade’s end to expand its
offering of anti-inflammatory therapies: to refresh the immunology franchise,
JNJ is directing R&D at promising next-generation biologics, including the
anti-interleukin (IL)-23 monoclonal antibody Guselkumab for psoriasis and rheumatoid
arthritis (RA); Sirukumab, an anti-interleukin (IL)-6 monoclonal antibody in
the treatment of patients with RA; and, an oral Janus Kinase (JAK) inhibitor
(ASP015K) for RA.
Management also told analysts at a recent
healthcare conference that new products are expected to comprise almost 46% of
pharmaceutical sales by 2017. Auspicious product launches across other disease
markets (including the blood thinner Xarelto, prostate cancer drug Zytiga,
hepatitis-C antiviral Incivo and interleukin inhibitor Stelara for psoriasis)
suggest JNJ is having early success in executing on its goal to lessen
dependence on Remicade through diversification.
Read more at YCharts: J&J’s Top Drug vs. Generic: Investment Thesis
Editor David J Phillips does not hold a
financial interest in any stocks mentioned in this article. The 10Q Detective
has a Full Disclosure Policy.
1 comment:
Thank you for the great article.
Post a Comment